Comparative Analysis of Cervical Human Papillomavirus DNA Testing and Cytological Findings among Women Presenting for “Pap” Smear in a Tertiary Health Centre in Northern Nigeria

Manga, Mohammed Mohammed; Fowotade, Adeola; Abdullahi, Yusuf; El-Nafaty, Aliyu Usman; Adamu, Sani; Bojude, A; Pindiga, H. U.; Bakare, Rasheed; Osoba, Abimbola O.

doi:10.9734/ijtdh/2016/23084

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bivalent and quadrivalent HPV vaccines provide protection coverage against HPV16 and HPV18; and HPV16, HPV18, HPV6 and HPV11 respectively [51, 52]. In addition, nonavalent HPV vaccine provides coverage against HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58 [51, 52]. In this study, the combined proportions of HPV16, HPV18, HPV31, HPV45, HPV52, HPV58 and HPV11 is 89.1%.…”

Section: Discussionmentioning

confidence: 91%

“…When taking cognizance of the available HPV vaccines (bivalent and quadrivalent HPV vaccines) and the recently introduced nonavalent vaccine (9vHPV), it can be deduced from this study that majority of HPV infections would be prevented. Bivalent and quadrivalent HPV vaccines provide protection coverage against HPV16 and HPV18; and HPV16, HPV18, HPV6 and HPV11 respectively [51, 52]. In addition, nonavalent HPV vaccine provides coverage against HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58 [51, 52].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the bivalent, quadrivalent and nonavalent HPV vaccines would respectively cover for 59.4%, 65.3% and 89.1% of the total HPVs observed in this study. The recently introduced nonavalent HPV vaccine was granted market authorization in the USA and Europe in the mid-2015 [51]. It is considered as a safe and effective vaccine and will further reduce the incidence of HPV infection and HPV-related cancers.…”

Section: Discussionmentioning

confidence: 99%

“…It is considered as a safe and effective vaccine and will further reduce the incidence of HPV infection and HPV-related cancers. It can also protect unvaccinated individuals through herd immunity [51, 52].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

Kabir¹,

Bukar²,

Nggada³

et al. 2019

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionCervical cancer is the commonest gynaecological malignancy and the second most common cancer among women worldwide. Several epidemiological, clinical and molecular studies have strongly implicated oncogenic high-risk human papillomavirus infection in the aetiopathogenesis of cervical cancer. The objectives of this study were to determine the cervical HPV prevalence and genotype distribution in cervical cancer in Maiduguri, Nigeria.MethodsThis was a descriptive and retrospective study. Sixty-three archived paraffin-embedded tissue blocks with confirmed diagnoses of cervical cancer during the study period (2013-2015) were retrieved and examined. The procedure included deparaffinization of tissue samples, DNA extraction, PCR, gel electrophoresis, and HPV genotyping by reverse hybridization line probe assay.ResultsSixty-three cervical cancer cases were subjected to genomic DNA extraction and HPV-DNA detection by PCR. Fifty-eight samples showed PCR positivity while 5 samples were PCR negative. HPV-specific DNA was detected in 44 of the 58 PCR-positive samples and thus the prevalence was 69.8%. Ten different high-risk HPV genotypes were detected. Both single and multiple high-risk HPV infections were observed. The most prevalent type of the human papillomavirus detected was HPV16.ConclusionHPV-DNA was prevalent in majority of the examined cervical cancer tissues and that HPV16, HPV18, HPV45, HPV51 and HPV52 were the predominant HPVs detected in both single and multiple HPV infections. The results of this study and further studies will provide more detailed information about HPV and may contribute significantly to the prevention of cervical cancer through primary high-risk HPV testing and HPV vaccination against the oncogenic viruses.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

Kabir¹,

Bukar²,

Nggada³

et al. 2019

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

Prevalence and Type Distribution of Human Papillomavirus Recovered from the Uterine Cervix of Nigerian Women: A Systematic Review and Meta-Analysis

Kabuga

Nejati

Arero

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Infection with an oncogenic type of human papillomavirus is a prerequisite for the development of precancerous cervical lesions and its subsequent progression to cervical cancer. With an alarming increase in the detection of other suspicious papillomavirus genotypes in both healthy and women with cervical lesions, there is a need for comprehensive data on cervical papillomavirus infection to address cervical cancer and other associated disease burden, especially in Sub-Sarahan Africa, where the bulk of the problem exists. The present study was conducted to develop comprehensive data on the prevalence and circulating genotypes of human papillomavirus in various risk categories in Nigeria. Methods: A systematic review and meta-analysis of peer-reviewed publications on cervical papillomavirus infection were performed. Relevant data were extracted from eligible studies published in PubMed, Web of Science, Embase, Scopus, and Google Scholar, from inception to July 31, 2019. The random-effect model was used to estimate the pooled prevalence. We identified 327 potential studies and pooled data from 18 studies, involving 5697 women aged 15-86 years. Results: The overall pooled prevalence of cervical papillomavirus infection was 42% (95%CI: 30-54%) in the general population and 37% (95%CI: 25-50%) among women living with HIV/AIDS, with the predominance of genotypes 16, 18, 31, 35, 52, 58 and 45. The highest prevalence was observed in teenagers and young adults and the second peak in women 50 years and above. Conclusion: The prevalence of cervical human papillomavirus infection is cumulatively high in Nigeria and HIV is a strong co-factor. We, therefore, strongly recommend the co-screening of human papillomavirus and cervical cancer and integration of the intervention strategy into the existing HIV-care guideline in Nigeria.

show abstract

Comparative Analysis of Cervical Human Papillomavirus DNA Testing and Cytological Findings among Women Presenting for “Pap” Smear in a Tertiary Health Centre in Northern Nigeria

Cited by 2 publications

References 18 publications

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria

Prevalence and Type Distribution of Human Papillomavirus Recovered from the Uterine Cervix of Nigerian Women: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About